Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
about
Interpreting molecular monitoring results and international standardization in chronic myeloid leukemia.Coexistence of JAK2 and BCR-ABL mutation in patient with myeloproliferative neoplasm.Low educational level but not low income impairs the achievement of cytogenetic remission in chronic myeloid leukemia patients treated with imatinib in Brazil.Comparison of the utility and applicability of the Sokal, Hasford, and EUTOS scores in a population of Chinese patients with chronic-phase chronic myeloid leukemia undergoing imatinib therapyNew Genetic Variation in BCR gene of Major B3a2 Breakpoint BCR-ABL Fusion Gene in Patients with Chronic Myelogenous Leukemia in Yogyakarta, IndonesiaSecond-generation TKIs: which and when?Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group.Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges.Oral cancer after prolonged immunosuppression for multiorgan chronic graft-versus-host diseaseManagement of advanced-phase chronic myeloid leukemia.cDNA synthesis for BCR-ABL1 detection at the MMR level: the importance of using the appropriate kit.Spontaneous Soft Tissue Haematomas- A Rare Presentation of Chronic Myeloid Leukemic (CML).Disparities in chronic myeloid leukemia survival by age, gender, and ethnicity in pre- and post-imatinib eras in the US.Cutaneous myeloid sarcoma associated with chronic myeloid leukemia.Mobile Health Intervention to Increase Oral Cancer Therapy Adherence in Patients With Chronic Myeloid Leukemia (The REMIND System): Clinical Feasibility and Acceptability Assessment.A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years.Molecular monitoring 101: helping your patients with chronic myeloid leukemia to understand the meaning of molecular response.Neuroendocrine tumor of cecum in patient treated with imatinib mesylate for blastic phase of chronic myeloid leukemia.First-line treatment of 102 chronic myeloid leukemia patients with imatinib: a long-term single institution analysis.The impact of introducing tyrosine kinase inhibitors on chronic myeloid leukemia survival: a population-based study
P2860
Q33885583-AF371885-FAEB-41AC-8EF1-F33A12868BB5Q35041677-06C17812-2712-4391-B7C5-CB7B16C302BBQ35666534-7FFA5425-A054-49AD-94EF-FFCAB7BD45BBQ36068354-7FD013A0-DF1E-437D-8242-30E57B825D8CQ36404921-3C31AA47-40CD-4D97-9285-54A42AB4C723Q36852243-FA67FE76-B42C-426B-9896-FF58EBD263B1Q37505017-EE7D9AEB-1156-4A16-8C1D-430288718AE9Q37618888-86580263-19DD-4C22-9096-9403B7188513Q37628627-DC2A2999-AD3B-4581-AF3B-0BE9F57AD33BQ38452040-1A2EA1F2-CC4C-4F1F-BCAC-0C0269FCC65EQ42128429-3B0EF475-E056-4754-8525-C2999AC92391Q42922031-EC538A63-6F96-4625-9591-8D3C8E883516Q46321644-E24E7642-499B-4EB3-8216-E1C26A76569EQ47123945-7A43DEA6-F1FA-47F3-AABC-3CA2376DA454Q47135575-3C651FB4-2C2F-44D6-90BC-6D09A01D8771Q50568120-0CFD71EE-58E5-4302-B17E-474B5748DCC5Q53136807-9F2A38FC-4C61-462C-BA35-BB8395066398Q53349509-D358FC81-606D-4D28-89D4-865D9EDB9672Q54336627-504F4D97-12AA-460E-A02C-70FC0EA74F44Q58605235-2D5F5C80-A935-43F5-916C-12B4A23412E7
P2860
Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Chronic myeloid leukaemia: ESM ...... osis, treatment and follow-up.
@ast
Chronic myeloid leukaemia: ESM ...... osis, treatment and follow-up.
@en
Chronic myeloid leukaemia: ESM ...... osis, treatment and follow-up.
@nl
type
label
Chronic myeloid leukaemia: ESM ...... osis, treatment and follow-up.
@ast
Chronic myeloid leukaemia: ESM ...... osis, treatment and follow-up.
@en
Chronic myeloid leukaemia: ESM ...... osis, treatment and follow-up.
@nl
prefLabel
Chronic myeloid leukaemia: ESM ...... osis, treatment and follow-up.
@ast
Chronic myeloid leukaemia: ESM ...... osis, treatment and follow-up.
@en
Chronic myeloid leukaemia: ESM ...... osis, treatment and follow-up.
@nl
P2093
P2860
P356
P1433
P1476
Chronic myeloid leukaemia: ESM ...... osis, treatment and follow-up.
@en
P2093
ESMO Guidelines Working Group
M Baccarani
M Dreyling
P2860
P304
P356
10.1093/ANNONC/MDQ201
P478
21 Suppl 5
P577
2010-05-01T00:00:00Z